Prudential Financial Inc Cerevel Therapeutics Holdings, Inc. Transaction History

Prudential Financial Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$20.27 - $42.44 $103,356 - $216,401	5,099 New	5,099 $216,000
Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $20,153 - $25,408	795 Added 2.9%	28,164 $0
Q3 2022 Nov 04, 2022	BUY	$25.5 - $41.42 $275,400 - $447,336	10,800 Added 65.18%	27,369 $773,000
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $43,095 - $77,643	2,090 Added 14.43%	16,569 $438,000
Q1 2022 May 13, 2022	BUY	$23.5 - $35.38 $340,256 - $512,267	14,479 New	14,479 $507,000
Q4 2021 Feb 14, 2022	SELL	$29.21 - $44.64 $306,705 - $468,720	-10,500 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $223,230 - $407,925	10,500 New	10,500 $310,000

242

154M

2.19M

3.87M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.